Eldar Tukanov

Dr. Eldar Tukanov

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RSRobin Stinissen
Robin Stinissen
ETEldar Tukanov
Eldar Tukanov
MWMartin Wyckmans
Martin Wyckmans
JKJeroen Kerstens
Jeroen Kerstens
BWBarbara Willekens
Barbara Willekens

7 September 2024 in Life
Verified
Journal Article
Open access
PDF file
ETEldar Tukanov
Eldar Tukanov
DLDorine Van Loo
Dorine Van Loo
Marijke DieltjensMarijke Dieltjens
Marijke Dieltjens
JVJohan Verbraecken
Johan Verbraecken
OVOlivier M Vanderveken
Olivier M Vanderveken
Sara Op de BeeckSara Op de Beeck
Sara Op de Beeck
Hypoglossal nerve stimulation (HGNS) has emerged as an effective treatment for obstructive sleep apnea (OSA). Identifying baseline characteristics that prospectively could predict treatment outcomes even better is crucial for optimizing patient selection and improving therapeutic success in the future. A systematic review was conducted following PRISMA guidelines. Literature searches in Medline, Web of Science, and Cochrane databases identified studies assessing baseline characteristics associated with HGNS treatment outcomes. Inclusion criteria focused on studies with adult patients diagnosed with OSA, treated with HGNS, and assessed using full-night efficacy sleep studies. Risk of bias was evaluated using the NICE tool. Twenty-six studies met the inclusion criteria. Commonly reported baseline characteristics with predictive potential included BMI, site of collapse, and various pathophysiological endotypes. Most studies used the original Sher criteria to define treatment response, though variations were noted. Results suggested that lower BMI, absence of complete concentric collapse at the palatal level, and specific pathophysiological traits were associated with better HGNS outcomes. This review identified several baseline characteristics associated with HGNS outcomes, which may guide future patient selection. Importantly, patients were already preselected for HGNS. Standardizing response criteria is recommended to enhance the evaluation and effectiveness of HGNS therapy in OSA patients.

6 May 2021 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
MWMartin Wyckmans
Martin Wyckmans
ETEldar Tukanov
Eldar Tukanov
RWRobbe Winters
Robbe Winters
RSRobin Stinissen
Robin Stinissen
HVHelene Vermeulen
Helene Vermeulen
LDLien Desteghe
Lien Desteghe

17 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ETEldar Tukanov
Eldar Tukanov
Marijke DieltjensMarijke Dieltjens
Marijke Dieltjens
AVAnnelies E. Verbruggen
Annelies E. Verbruggen
AVAnneclaire V. Vroegop
Anneclaire V. Vroegop
JVJohan Verbraecken
Johan Verbraecken
OVOlivier M Vanderveken
Olivier M Vanderveken
Background: Mandibular advancement device (MAD) therapy is a non-invasive treatment for obstructive sleep apnea (OSA). Although the effect of MAD on OSA outcomes is widely known, its effect on the upper airway collapse degree remains poorly understood. This study aimed to assess the impact of MAD therapy on site-specific airway collapse degree during drug-induced sleep endoscopy (DISE). Methods: One hundred participants were recruited and underwent a baseline polysomnography. Overall, 69 participants with OSA (AHI 5–50 events/h) underwent DISE at baseline and with MAD set to 75% of maximal mandibular protrusion. Collapse degree (none, partial, complete) was evaluated at the palate, oropharynx, tongue base, hypopharynx, and epiglottis without and with MAD. Ordinal logistic regression was used to analyze changes in degree of collapse. Results: MAD therapy reduced collapse degree at the palate (OR = 5.92 [3.28; 10.66], p < 0.001), oropharynx (OR = 2.70 [1.48; 4.92], p = 0.001), tongue base (OR = 1.83 [1.32; 2.53], p < 0.001), and hypopharynx (OR = 2.90 [1.53; 5.48, p = 0.001), with no effect at the epiglottis (OR = 0.65 [0.42; 1.02], p = 0.058). Conclusions: MAD therapy reduces upper airway collapse at most anatomical levels, except at the level of the epiglottis. These findings confirm its therapeutic efficacy while underscoring the importance of identifying patients with residual or worsening collapse who may benefit from combined or alternative treatments.

20 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DLDorine Van Loo
Dorine Van Loo
ETEldar Tukanov
Eldar Tukanov
Marijke DieltjensMarijke Dieltjens
Marijke Dieltjens
Sara Op de BeeckSara Op de Beeck
Sara Op de Beeck
EPEli Van De Perck
Eli Van De Perck
OVOlivier M Vanderveken
Olivier M Vanderveken
Background: Respiration-synchronized hypoglossal nerve stimulation (HGNS) is an effective treatment option for selected patients with obstructive sleep apnea (OSA). While literature on the standardization of the post-implant care pathway for patients treated with HGNS therapy remains limited, the growing global use of HGNS has made structured post-implant care management increasingly important. Methods: This narrative review summarizes the advancements related to the clinical pathway for respiration-synchronized HGNS therapy over the past 5 years, with a special focus on post-implant care management. Results: Selection criteria for respiration-synchronized HGNS are changing as new clinical findings emerge, including both anatomical and non-anatomical markers. Evidence suggests that adopting single-amplitude, full-night sleep testing may provide a more reliable assessment of HGNS treatment efficacy. Several studies have described optimization strategies for patients with suboptimal HGNS therapy response or therapy-related discomfort, including the use of awake endoscopy and drug-induced sleep endoscopy for advanced HGNS programming and the use of combination therapy, although data remains limited. Conclusions: The clinical care pathway for respiration-synchronized HGNS continues to evolve, including patient selection, evaluation of treatment success, and strategies for managing incomplete responders or patients with therapy-related discomfort. Nonetheless, addressing insufficient treatment responses remains a significant challenge and a key area for future research and clinical optimization.